ReviewImmunotherapy2011
Current landscape for T-cell targeting in autoimmunity and transplantation.
Review in Immunotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Dynamics of virus-specific T cell immunity in pediatric liver transplant recipients.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2018Trial
- The pharmacokinetics and pharmacodynamics of TOL101, a murine IgM anti-human αβ T cell receptor antibody, in renal transplant patients.Clinical pharmacokinetics · 2014Trial
- First-in-human study of the safety and efficacy of TOL101 induction to prevent kidney transplant rejection.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2014Trial
- Hydrogel-based approaches to target hypersensitivity mechanisms underlying autoimmune disease.Advanced drug delivery reviews · 2024Review
- Bioengineered particles expand myelin-specific regulatory T cells and reverse autoreactivity in a mouse model of multiple sclerosis.Science advances · 2023Article
- Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects.Archives of gynecology and obstetrics · 2022Article
- What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021Article
- Recurrent squamous cell carcinoma in a post cardiac transplant patient.International journal of surgery case reports · 2021Article
- Evaluation of ultra-low input RNA sequencing for the study of human T cell transcriptome.Scientific reports · 2019Article
- Cathepsin S Is Involved in Th17 Differentiation Through the Upregulation of IL-6 by Activating PAR-2 after Systemic Exposure to Lipopolysaccharide fromFrontiers in pharmacology · 2017Article
- Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Suppression of IL-7-dependent Effector T-cell Expansion by Multipotent Adult Progenitor Cells and PGE2.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Activation of the peroxisome proliferator-activated receptor γ counteracts sepsis-induced T cell cytotoxicity toward alloantigenic target cells.Journal of molecular medicine (Berlin, Germany) · 2015Article
- Is hypertension an autoimmune disease?The Journal of clinical investigation · 2014Article
- Immunosuppressive and anti-inflammatory properties of engineered nanomaterials.British journal of pharmacology · 2014Review
- Lung transplantation: chronic allograft dysfunction and establishing immune tolerance.Human immunology · 2014Review
- Tolerance induction in memory CD4 T cells requires two rounds of antigen-specific activation.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Biological evaluation of subglutinol a as a novel immunosuppressive agent for inflammation intervention.ACS medicinal chemistry letters · 2014Article
- Immunosuppressive peptides and their therapeutic applications.Drug discovery today · 2014Review
- The immunogenicity of cells derived from induced pluripotent stem cells.Cellular & molecular immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In recent years, substantial advances in T-cell immunosuppressive strategies and their translation to routine clinical practice have revolutionized management and outcomes in autoimmune disease and solid organ transplantation. More than 80 diseases have been considered to have an autoimmune etiology, such that autoimmune-associated morbidity and mortality rank as third highest in developed countries, after cardiovascular diseases and cancer. Solid organ transplantation has become the therapy of choice for many end-stage organ diseases. Short-term outcomes such as patient and allograft survival at 1 year, acute rejection rates, as well as time course of disease progression and symptom control have steadily improved. However, despite the use of newer immunosuppressive drug combinations, improvements in long-term allograft survival and complete resolution of autoimmunity remain elusive. In addition, the chronic use of nonspecifically targeted immunosuppressive drugs is associated with significant adverse effects and increased morbidity and mortality. In this article, we discuss the current clinical tools for immune suppression and attempts to induce long-term T-cell tolerance induction as well as much-needed future approaches to produce more short-acting, antigen-specific agents, which may optimize outcomes in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.